SAREPTA THERAPEUTICS, INC. Increase (Decrease) in Accounts Receivable
SAREPTA THERAPEUTICS, INC. (SRPT) reported Increase (Decrease) in Accounts Receivable of -$21.41 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-05
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$17.99M.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$3.42M, a 105.95% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $2.49M, a 98.51% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$131.56M, a 276.52% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2025 was -$203.75M, a 201.04% decline from fiscal 2024.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2024 was $201.66M, a 8.60% increase from fiscal 2023.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2023 was $185.70M, a 201.27% increase from fiscal 2022.
- SAREPTA THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2022 was $61.64M, a 19.34% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$17.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$21.41M 10-Q · filed 2026-08-05 | -$18.91M derived: sum of 3 quarters · filed 2026-08-05 | -$150.47M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$3.42M 10-Q · filed 2026-05-06 | -$922.00K derived: sum of 2 quarters · filed 2026-05-06 | -$132.48M derived: sum of 3 quarters · filed 2026-05-06 | -$264.55M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$129.06M derived: sum of 2 quarters · filed 2026-03-02 | -$261.14M derived: sum of 3 quarters · filed 2026-08-05 | -$203.75M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$131.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$263.63M derived: sum of 2 quarters · filed 2026-08-05 | -$206.25M 10-Q · filed 2025-11-06 | -$38.78M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$132.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$74.69M 10-Q · filed 2026-08-05 | $92.77M derived: sum of 3 quarters · filed 2026-08-05 | $167.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $57.38M 10-Q · filed 2026-05-06 | $224.85M derived: sum of 2 quarters · filed 2026-05-06 | $299.37M derived: sum of 3 quarters · filed 2026-05-06 | $280.56M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $167.46M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $241.99M derived: sum of 2 quarters · filed 2026-03-02 | $223.18M derived: sum of 3 quarters · filed 2026-03-02 | $201.66M 10-K · filed 2026-03-02 |
| 2024-09-30 | $74.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $55.72M derived: sum of 2 quarters · filed 2025-11-06 | $34.20M 10-Q · filed 2025-11-06 | $115.67M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$18.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$40.33M 10-Q · filed 2025-08-06 | $41.14M derived: sum of 3 quarters · filed 2026-03-02 | $123.19M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$21.52M 10-Q · filed 2025-05-06 | $59.95M derived: sum of 2 quarters · filed 2026-03-02 | $142.00M derived: sum of 3 quarters · filed 2026-03-02 | $154.97M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $81.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $163.52M derived: sum of 2 quarters · filed 2026-03-02 | $176.49M derived: sum of 3 quarters · filed 2026-03-02 | $185.70M 10-K · filed 2026-03-02 |
| 2023-09-30 | $82.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $95.02M derived: sum of 2 quarters · filed 2024-11-06 | $104.23M 10-Q · filed 2024-11-06 | $117.35M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $12.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $22.18M 10-Q · filed 2024-08-07 | $35.30M derived: sum of 3 quarters · filed 2025-02-28 | $32.95M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $9.21M 10-Q · filed 2024-05-01 | $22.33M derived: sum of 2 quarters · filed 2025-02-28 | $19.98M derived: sum of 3 quarters · filed 2025-02-28 | $45.64M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $13.12M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $10.77M derived: sum of 2 quarters · filed 2025-02-28 | $36.43M derived: sum of 3 quarters · filed 2025-02-28 | $61.64M 10-K · filed 2025-02-28 |
| 2022-09-30 | -$2.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $23.32M derived: sum of 2 quarters · filed 2023-11-01 | $48.52M 10-Q · filed 2023-11-01 | $51.72M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $25.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $50.86M 10-Q · filed 2023-08-02 | $54.07M derived: sum of 3 quarters · filed 2024-02-28 | $76.33M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $25.20M 10-Q · filed 2023-05-02 | $28.41M derived: sum of 2 quarters · filed 2024-02-28 | $50.67M derived: sum of 3 quarters · filed 2024-02-28 | $59.99M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $25.47M derived: sum of 2 quarters · filed 2024-02-28 | $34.79M derived: sum of 3 quarters · filed 2024-02-28 | $51.65M 10-K · filed 2024-02-28 |
| 2021-09-30 | $22.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $31.58M derived: sum of 2 quarters · filed 2022-11-02 | $48.45M 10-Q · filed 2022-11-02 | $27.96M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $9.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $26.18M 10-Q · filed 2022-08-02 | $5.69M derived: sum of 3 quarters · filed 2023-02-28 | $23.49M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $16.86M 10-Q · filed 2022-05-04 | -$3.62M derived: sum of 2 quarters · filed 2023-02-28 | $14.18M derived: sum of 3 quarters · filed 2023-02-28 | $11.33M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$20.49M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$2.69M derived: sum of 2 quarters · filed 2023-02-28 | -$5.54M derived: sum of 3 quarters · filed 2023-02-28 | $10.46M 10-K · filed 2023-02-28 |
| 2020-09-30 | $17.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $14.95M derived: sum of 2 quarters · filed 2021-11-03 | $30.95M 10-Q · filed 2021-11-03 | $53.80M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$2.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $13.15M 10-Q · filed 2021-08-04 | $36.00M derived: sum of 3 quarters · filed 2022-03-01 | $47.05M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $16.00M 10-Q · filed 2021-05-05 | $38.84M derived: sum of 2 quarters · filed 2022-03-01 | $49.89M derived: sum of 3 quarters · filed 2022-03-01 | $56.37M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $22.85M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $33.90M derived: sum of 2 quarters · filed 2022-03-01 | $40.37M derived: sum of 3 quarters · filed 2022-03-01 | $41.84M 10-K · filed 2022-03-01 |
| 2019-09-30 | $11.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $17.52M derived: sum of 2 quarters · filed 2020-11-05 | $18.99M 10-Q · filed 2020-11-05 | $19.43M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $6.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $7.94M 10-Q · filed 2020-08-05 | $8.38M derived: sum of 3 quarters · filed 2021-03-01 | $14.00M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $1.47M 10-Q · filed 2020-05-06 | $1.91M derived: sum of 2 quarters · filed 2021-03-01 | $7.53M derived: sum of 3 quarters · filed 2021-03-01 | $10.66M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $443.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $6.06M derived: sum of 2 quarters · filed 2021-03-01 | $9.20M derived: sum of 3 quarters · filed 2021-03-01 | $19.58M 10-K · filed 2021-03-01 |
| 2018-09-30 | $5.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $8.75M derived: sum of 2 quarters · filed 2019-11-07 | $19.13M 10-Q · filed 2019-11-07 | $23.85M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-06-30 | $3.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $13.52M 10-Q · filed 2019-08-07 | $18.23M derived: sum of 3 quarters · filed 2020-02-26 | $25.19M derived: sum of 4 quarters · filed 2020-02-26 |
| 2018-03-31 | $10.38M 10-Q · filed 2019-05-08 | $15.10M derived: sum of 2 quarters · filed 2020-02-26 | $22.06M derived: sum of 3 quarters · filed 2020-02-26 | $27.57M derived: sum of 4 quarters · filed 2020-02-26 |
| 2017-12-31 | $4.72M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $11.68M derived: sum of 2 quarters · filed 2020-02-26 | $17.19M derived: sum of 3 quarters · filed 2020-02-26 | $24.24M 10-K · filed 2020-02-26 |
| 2017-09-30 | $6.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $12.47M derived: sum of 2 quarters · filed 2018-10-31 | $19.52M 10-Q · filed 2018-10-31 | $20.77M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $5.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $12.56M 10-Q · filed 2018-08-08 | $13.80M derived: sum of 3 quarters · filed 2019-02-28 | $13.81M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $7.05M 10-Q · filed 2018-05-03 | $8.29M derived: sum of 2 quarters · filed 2019-02-28 | $8.30M derived: sum of 3 quarters · filed 2019-02-28 | $8.29M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $1.25M derived: sum of 2 quarters · filed 2019-02-28 | $1.24M derived: sum of 3 quarters · filed 2019-02-28 | $1.25M 10-K · filed 2019-02-28 |
| 2016-09-30 | $4.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$4.00K derived: sum of 2 quarters · filed 2017-11-01 | $9.00K 10-Q · filed 2017-11-01 | $1.25M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | -$8.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $5.00K 10-Q · filed 2017-08-03 | $1.25M derived: sum of 3 quarters · filed 2018-03-01 | |
| 2016-03-31 | $13.00K 10-Q · filed 2017-05-04 | $1.26M derived: sum of 2 quarters · filed 2018-03-01 | ||
| 2015-12-31 | $1.24M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $1.56M 10-K · filed 2018-03-01 | ||
| 2015-09-30 | $317.00K 10-Q · filed 2016-11-07 | |||
| 2014-12-31 | -$946.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$2.81M derived: sum of 2 quarters · filed 2017-02-28 | -$5.43M derived: sum of 3 quarters · filed 2017-02-28 | -$1.11M 10-K · filed 2017-02-28 |
| 2014-09-30 | -$1.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | -$4.49M derived: sum of 2 quarters · filed 2015-11-05 | -$168.00K 10-Q · filed 2015-11-05 | -$3.36M derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | -$2.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $1.70M 10-Q · filed 2015-08-06 | -$1.50M derived: sum of 3 quarters · filed 2016-02-25 | |
| 2014-03-31 | $4.32M 10-Q · filed 2015-05-07 | $1.13M derived: sum of 2 quarters · filed 2016-02-25 | ||
| 2013-12-31 | -$3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | -$1.18M 10-K · filed 2016-02-25 | ||
| 2013-09-30 | $2.01M 10-Q · filed 2014-11-06 | |||
| 2012-12-31 | $1.08M 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |